North America Rare Biomarkers Specimen Collection And Stabilization Market Size & Outlook
North America rare biomarkers specimen collection and stabilization market, 2018-2030 (US$M)
Related Markets
North America rare biomarkers specimen collection and stabilization market highlights
- The North America rare biomarkers specimen collection and stabilization market generated a revenue of USD 21,864.8 million in 2024.
- The market is expected to grow at a CAGR of 14.5% from 2025 to 2030.
- In terms of segment, circulating cell free dna (ccfdna) was the largest revenue generating biomarker in 2024.
- Circulating Cell Free RNA (ccfRNA) / miRNA is the most lucrative biomarker segment registering the fastest growth during the forecast period.
- Country-wise, U.S. is expected to register the highest CAGR from 2025 to 2030.
North America data book summary
| Market revenue in 2024 | USD 21,864.8 million |
| Market revenue in 2030 | USD 48,609.9 million |
| Growth rate | 14.5% (CAGR from 2025 to 2030) |
| Largest segment | Circulating cell free dna (ccfdna) |
| Fastest growing segment | Circulating Cell Free RNA (ccfRNA) / miRNA |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes/Extracellular Vesicles, Circulating Cell Free RNA (ccfRNA) / miRNA |
| Key market players worldwide | Qiagen NV, Charles River Laboratories International Inc, Roche Holding AG ADR, Thermo Fisher Scientific Inc, Eurofins Scientific SE, PerkinElmer, Bio-Rad Laboratories Inc, Agilent Technologies Inc, Merck KGaA, Siemens Healthineers AG ADR |
Other key industry trends
- In terms of revenue, North America region accounted for 52.1% of the global rare biomarkers specimen collection and stabilization market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 16,418.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Rare Biomarkers Specimen Collection And Stabilization Market Scope
Rare Biomarkers Specimen Collection And Stabilization Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America rare biomarkers specimen collection and stabilization market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare biomarkers specimen collection and stabilization market will help companies and investors design strategic landscapes.
Circulating cell free dna (ccfdna) was the largest segment with a revenue share of 40.11% in 2024. Horizon Databook has segmented the North America rare biomarkers specimen collection and stabilization market based on circulating cell free dna (ccfdna), circulating tumor cells (ctcs), exosomes/extracellular vesicles, circulating cell free rna (ccfrna) / mirna covering the revenue growth of each sub-segment from 2018 to 2030.
Key factors contributing to the large revenue share of this regional market include presence of a wide client base coupled with a substantial number of FDA-approved products. The number of approved biomarker isolation kits for both clinical use and research use is anticipated to increase with expanding liquid biopsy and assisted reproductive technology space.
In addition, ongoing conferences in the region pertaining to the role of biomarkers in disease management are driving the regional growth.
For instance, in January 2020, researchers at Vall d´Hebron University Hospital illustrated the correlation between the clearance of ctDNA in patients with breast cancer who underwent neoadjuvant treatment; in the Liquid Biopsies conference held in Miami, Florida.
Reasons to subscribe to North America rare biomarkers specimen collection and stabilization market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America rare biomarkers specimen collection and stabilization market databook
-
Our clientele includes a mix of rare biomarkers specimen collection and stabilization market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America rare biomarkers specimen collection and stabilization market , including forecasts for subscribers. This continent databook contains high-level insights into North America rare biomarkers specimen collection and stabilization market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
North America rare biomarkers specimen collection and stabilization market size, by country, 2018-2030 (US$M)
North America Rare Biomarkers Specimen Collection And Stabilization Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
